TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17928596

Group type: EXPERIMENTAL
Intervention: Colonization with S. pneumoniae, M. catarrhalis, H. influenzae, or a combination of these organisms
Number of subjects: 321
Study: 15385732

Group type: EXPERIMENTAL
Intervention: AMD3100 at 5 microg/kg/h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AMD3100 at 40 microg/kg/h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AMD3100 at 80 microg/kg/h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AMD3100 at 160 microg/kg/h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AMD3100 (all doses)
Number of subjects: 40
Study: 11519973

Group type: EXPERIMENTAL
Intervention: Iron-fortified cow's milk (7.0 or 14.9 mg Fe l(‐1))
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unfortified cow's milk
Number of subjects: 36
Study: 9683847

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin and adriamycin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with ifosfamide and etoposide added to cisplatin and adriamycin for poor histologic response
Number of subjects: 29

Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 29
Study: 8150787

Group type: EXPERIMENTAL
Intervention: Thyroid function indices (TSH, T3, T4) in ADHD subjects
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal controls (age and gender-matched), N=41
Number of subjects: 53
Study: 3207530

Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 12
Study: 31990490

Group type: EXPERIMENTAL
Intervention: accelerated intermittent theta burst stimulation (aiTBS) applied to the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 40
Study: 29352071

Group type: EXPERIMENTAL
Intervention: Aggressive diuresis with high-dose loop diuretics (median 560 mg IV furosemide equivalents)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Aggressive diuresis with high-dose loop diuretics
Number of subjects: 283
Study: 27510532

Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation (ONS) during HD sessions for 12 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation (ONS) + Resistance Exercise (RE) during HD sessions for 12 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group receiving ONS
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intervention group receiving ONS + RE
Number of subjects: 36
Study: 24992949

Group type: EXPERIMENTAL
Intervention: Oral prednisone for 8 days in tapering doses
Number of subjects: 265

Group type: COMPARATOR
Intervention: Intratympanic prednisolone at a dose of 62.5 mg/ml once a day for 3 consecutive days
Number of subjects: 265
Study: 22995032

Group type: EXPERIMENTAL
Intervention: Olive oil applied twice daily for 5 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sunflower seed oil applied twice daily for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Olive oil compared to sunflower seed oil
Number of subjects: 19
Study: 20391510

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg every other day)
Number of subjects: 39144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39144
Study: 18232726

Group type: EXPERIMENTAL
Intervention: High-dose olanzapine (mean dose, 34 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clozapine (mean dose, 564 mg/day)
Number of subjects: 40
Study: 16763775

Group type: EXPERIMENTAL
Intervention: Experience Corps (EC) participants
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Experience Corps (EC) participants with low activity at baseline
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waiting list control group with low activity at baseline
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Previously active EC participants
Number of subjects: 113
Study: 11860612

Group type: EXPERIMENTAL
Intervention: Norepinephrine (10 micrograms in 0.1 ml saline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (0.1 ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 20
Study: 10353373

Group type: EXPERIMENTAL
Intervention: Simple feature search
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjoined feature search
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experimental test session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target detection
Number of subjects: 0
Study: 7866980

Group type: EXPERIMENTAL
Intervention: COACHING protocol
Number of subjects: 18

Group type: COMPARATOR
Intervention: NOT‐COACHED (usual care)
Number of subjects: 18
Study: 1772457

Group type: EXPERIMENTAL
Intervention: Hemodialysate injection (10 ml, 400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hemodialysate infusion (500 ml, 4 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo injection (saline)
Number of subjects: 12
Study: 7043868

Group type: EXPERIMENTAL
Intervention: Scleral buckling operation with drainage of subretinal fluid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Scleral buckling operation without drainage of subretinal fluid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (drainage and nondrainage)
Number of subjects: 120
Study: 31094772

Group type: EXPERIMENTAL
Intervention: High MAP (HMAP; 70-80 mm Hg)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Low MAP (LMAP; 40-50 mm Hg)
Number of subjects: 176
Study: 28822007

Group type: EXPERIMENTAL
Intervention: 3 × 3 dose-dense cycles of intensified epirubicin, paclitaxel, and cyclophosphamide (ETC)
Number of subjects: 163

Group type: COMPARATOR
Intervention: 4 cycles concurrent epirubicin and cyclophosphamide followed by 10 cycles of weekly paclitaxel combined with 4 cycles capecitabine (EC-TX)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: ETC treatment
Number of subjects: 163
Study: 24206399

Group type: EXPERIMENTAL
Intervention: Solitaire FR embolectomy device
Number of subjects: 690

Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 690
Study: 24227635

Group type: EXPERIMENTAL
Intervention: Sertraline 50mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 22558108

Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF) - daily supplemental RUTF (high-protein peanut-based paste) for 14 days
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group - no supplemental food
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF)
Number of subjects: 180
Study: 19523596

Group type: COMPARATOR
Intervention: RCTs published in high-ranked journals
Number of subjects: 261

Group type: COMPARATOR
Intervention: RCTs published in low-ranked journals
Number of subjects: 261

Group type: COMPARATOR
Intervention: Pre-CONSORT period (1988-1995)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Post-CONSORT period (1996-2008)
Number of subjects: 261
Study: 17544888

Group type: EXPERIMENTAL
Intervention: PaCO(2) increased from 30 to 40 mmHg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PaCO(2) increased to 50 mmHg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PaCO(2) returned to 30 mmHg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PaCO(2) increased
Number of subjects: 17
Study: 15385367

Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Horizontal position
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 10
Study: 11442499

Group type: EXPERIMENTAL
Intervention: Clodronate (1600 mg/d)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study: 10588606

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 11
Study: 8573450

Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 346

Group type: COMPARATOR
Intervention: Non-oophorectomized women
Number of subjects: 346

Group type: COMPARATOR
Intervention: Oophorectomized women
Number of subjects: 346
Study: 2150785

Group type: EXPERIMENTAL
Intervention: Single administration of 250 mg of caffeine (a)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Continuous administration of 250 mg caffeine per day for 5 days (c)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (p)
Number of subjects: 7
Study: 91500

Group type: EXPERIMENTAL
Intervention: 4 different stimulation frequencies during the task
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 4 different stimulation frequencies during rest
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 4 different stimulation frequencies during the final rest period
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Lower stimulation frequencies
Number of subjects: 84
Study: 30346186

Group type: EXPERIMENTAL
Intervention: M-CBT (N = 52)
Number of subjects: 102

Group type: COMPARATOR
Intervention: CBT (N = 50)
Number of subjects: 102
Study: 27041269

Group type: EXPERIMENTAL
Intervention: Ambu aScope 3 Slim
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olympus LF-GP
Number of subjects: 20
Study: 25134312

Group type: EXPERIMENTAL
Intervention: Moisturising leave‐on lotion (LOL) containing 10% glycerol, applied 3 times per week for 8 weeks.
Number of subjects: 0
Study: 23588449

Group type: EXPERIMENTAL
Intervention: High dietary vitamin K intake
Number of subjects: 132

Group type: COMPARATOR
Intervention: Low dietary vitamin K intake
Number of subjects: 132
Study: 20358470

Group type: EXPERIMENTAL
Intervention: 10 servings/day of botanically defined fruits and vegetables for 2 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: UGT1A1*28 polymorphism
Number of subjects: 28
Study: 18329881

Group type: EXPERIMENTAL
Intervention: Cystic tumors
Number of subjects: 58

Group type: COMPARATOR
Intervention: Solid tumors
Number of subjects: 58
Study: 16372492

Group type: EXPERIMENTAL
Intervention: Intravenous irinotecan plus oral ciclosporin
Number of subjects: 34
Study: 12730797

Group type: COMPARATOR
Intervention: SR 1 g/day
Number of subjects: 513

Group type: COMPARATOR
Intervention: SR 2 g/day
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: SR (higher-dose group)
Number of subjects: 513

Group type: COMPARATOR
Intervention: SR
Number of subjects: 513
Study: 10378604

Group type: EXPERIMENTAL
Intervention: Short chain fatty acid enemas
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8675080

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg four times daily orally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1736933

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg/daily) with weight loss
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/daily) with weight loss
Number of subjects: 878

Group type: COMPARATOR
Intervention: Placebo with usual diet
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Chlorthalidone with sodium restriction
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Atenolol with sodium restriction
Number of subjects: 878

Group type: COMPARATOR
Intervention: Placebo with weight reduction (lost more than 4.5 kg)
Number of subjects: 878

Group type: COMPARATOR
Intervention: Sodium restriction (reduced sodium to less than 70 mEq daily)
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Weight loss/atenolol subgroup
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Usual diet/chlorthalidone subgroup
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 878

Group type: COMPARATOR
Intervention: Chlorthalidone and usual diet
Number of subjects: 878
Study: 6228913

Group type: EXPERIMENTAL
Intervention: Aspirin (1 g/day)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Aspirin (1 g) + Dipyridamole (225 mg)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 604
Study: 3894598

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 0
Study: 29969473

Group type: EXPERIMENTAL
Intervention: Increased plasma concentrations of IL‐6, IL‐8, and IL‐10 at wound closure and 24 hours after surgery
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IL‐6 and IL‐8 levels above the 3rd quartile measured on the first postoperative day
Number of subjects: 96
Study: 26407603

Group type: COMPARATOR
Intervention: ABT-436 100 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ABT-436 500 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ABT-436 800 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ABT-436 200 mg (morning regimen)
Number of subjects: 29

Group type: COMPARATOR
Intervention: ABT-436 200 mg (evening regimen)
Number of subjects: 29
Study: 25503455

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 114
Study: 22683955

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich beverage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard preoperative regime (nothing by mouth)
Number of subjects: 40
Study: 20152042

Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate (1500 mg per day for 6 weeks) followed by a 12-week progressive walking program (3000 to 6000 steps/day)
Number of subjects: 36
Study: 18518726

Group type: EXPERIMENTAL
Intervention: 16-slice computed tomography (CT) angiography
Number of subjects: 244

Group type: COMPARATOR
Intervention: Conventional digital subtraction (DS) angiography
Number of subjects: 244
Study: 15782751

Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia guideline implementation
Number of subjects: 510
Study: 14602757

Group type: EXPERIMENTAL
Intervention: Immediate-release glipizide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glipizide GITS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 15
Study: 11177189

Group type: EXPERIMENTAL
Intervention: Moderate fat content breakfast (M)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low fat content breakfast (L)
Number of subjects: 24
Study: 8792788

Group type: EXPERIMENTAL
Intervention: Quality assurance interventions
Number of subjects: 16
Study: 1614804

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa2 (reaferon) combined with antioxidants (tocopherol)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Tocopherol alone
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 73
Study: 6203288

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (opiate antagonist)
Number of subjects: 0
Study: 30699314

Group type: EXPERIMENTAL
Intervention: Bilateral internal-thoracic-artery grafting
Number of subjects: 3102

Group type: COMPARATOR
Intervention: Single internal-thoracic-artery grafting
Number of subjects: 3102
Study: 30526923

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Subarachnoid (spinal) anesthesia (S group)
Number of subjects: 70
Study: 26477027

Group type: EXPERIMENTAL
Intervention: Strictly Monitored Exercise Programs (SMEP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual Care Program (UCP)
Number of subjects: 60
Study: 23426563

Group type: EXPERIMENTAL
Intervention: Kinesio taping treatment for gastrocnemius muscle enhancement and ankle functional correction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo control group for simulated Kinesio taping
Number of subjects: 120
Study: 22323240

Group type: EXPERIMENTAL
Intervention: Chickpea
Number of subjects: 28

Group type: COMPARATOR
Intervention: Soybean meal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Chickpea and faba bean
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diet (all sources)
Number of subjects: 28
Study: 20664017

Group type: EXPERIMENTAL
Intervention: Electronic insulin order template
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual insulin ordering
Number of subjects: 128
Study: 18246990

Group type: EXPERIMENTAL
Intervention: Coffee (200 mg of caffeine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Napping (30 minutes)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee, 15 mg of caffeine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Napping
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 24
Study: 15883636

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg/day
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg/day
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1637
Study: 12393621

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo (iron)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo (sulfadoxine-pyrimethamine)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Current or recent malarial infection
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Disappearance of malarial antigenemia
Number of subjects: 328
Study: 11515632

Group type: EXPERIMENTAL
Intervention: Flumazenil 2 mg iv (group A)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Flumazenil (group A)
Number of subjects: 54
Study: 9016467

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 12
Study: 1642477

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study: 6388048

Group type: EXPERIMENTAL
Intervention: Sensorad
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sensorad (in carcinoma uteri)
Number of subjects: 42
Study: 31336290

Group type: EXPERIMENTAL
Intervention: Pictorial health warnings
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Health warnings
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Health warnings with quitline
Number of subjects: 870
Study: 29264937

Group type: EXPERIMENTAL
Intervention: PCT-guided antibiotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 28389137

Group type: EXPERIMENTAL
Intervention: High-sugar protein shake (believed to be healthy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-sugar protein shake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-sugar protein shake (labeled as healthy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-sugar protein shake (labeled as indulgent)
Number of subjects: 0
Study: 26220089

Group type: EXPERIMENTAL
Intervention: Psychodynamic group therapy
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 199

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 199
Study: 24200220

Group type: EXPERIMENTAL
Intervention: Proton SBRT (50Gy in 4 fractions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Photon SBRT (50Gy in 4 fractions)
Number of subjects: 10
Study: 21427564

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1.5 mg/kg body weight/d
Number of subjects: 15

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 15
Study: 18799092

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily
Number of subjects: 834

Group type: COMPARATOR
Intervention: Celecoxib 200 mg once daily
Number of subjects: 834

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study: 16434136

Group type: EXPERIMENTAL
Intervention: Screening arm (PSA testing every 4 years)
Number of subjects: 42176

Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 42176

Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 42176

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 42176
Study: 14655198

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg plus 7 sevelamer hydrochloride 403 mg capsules (Arm B)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg plus 4 calcium acetate 667 mg tablets (Arm C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ciprofloxacin 750 mg alone (Arm A)
Number of subjects: 15
Study: 11247403

Group type: EXPERIMENTAL
Intervention: Cystatin C concentration
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Antipapain activity
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Antitrypsin activity
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cystatin C concentration in patients with microangiopathy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Antipapain and antitrypsin activities
Number of subjects: 72
Study: 9262430

Group type: EXPERIMENTAL
Intervention: Coca chewing (15 g of coca leaves)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sugar-free chewing gum (Coca‐ trial)
Number of subjects: 16
Study: 8268557

Group type: EXPERIMENTAL
Intervention: On-line automated method for measurement of dialyzer electrolyte clearance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetitive electrolyte clearance data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algorithms for calculating delivered Kt/V
Number of subjects: 0
Study: 3101386

Group type: EXPERIMENTAL
Intervention: Buprenorphine 10 micrograms X kg‐1
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Buprenorphine 20 micrograms X kg‐1
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Buprenorphine 30 micrograms X kg‐1
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Buprenorphine 40 micrograms X kg‐1
Number of subjects: 52
Study: 30144513

Group type: EXPERIMENTAL
Intervention: Baseline LBP and time‐integrated concentration (TIC) of LBP over 12 and 18 months
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Baseline sTLR4 and TIC over 18 months
Number of subjects: 431
Study: 27105047

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day (moderate intensity)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atorvastatin 60 mg/day (high intensity)
Number of subjects: 21
Study: 24952726

Group type: EXPERIMENTAL
Intervention: Transvaginal cholecystectomy (TVC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Needlescopic cholecystectomy (NC)
Number of subjects: 40